The German firm is buying Frame Cancer Therapeutics in a deal valued at €32m, with CEO Franz-Werner Haas claiming that it will help the firm in its search for promising neoantigens for its mRNA cancer vaccine programs.

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

French biotech says it has adequate Phase II data to design a pivotal study with regulators, but needs trial funding and a big pharma partner.

Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in February 2017.